New Drug Delivery Systems (NDDS) Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.46 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
New Drug Delivery Systems (NDDS) Market Analysis
The Novel Drug Delivery Systems (NDDS) Market is expected to grow from USD 269.10 billion in 2023 to USD 350.97 billion in 2028, registering a CAGR of 5.46% during the forecast period.
The emergence of the COVID-19 pandemic significantly impacted the novel drug delivery systems market due to supply chain disruptions and delayed clinical trials for new drug delivery systems due to restrictions on non-essential research activities, site closures, and challenges in patient recruitment. Additionally, the pharmaceutical and biotech industry's resources were redirected toward COVID-19 vaccine development and related research, which diverted attention and resources away from developing novel drug delivery systems for other therapeutic areas and impacted the growth of the NDDS market. For instance, during the initial phase of the COVID-19 pandemic, AstraZeneca received more than USD 1,000 million in funding from the United States Health Department's Biomedical Advanced Research and Development Authority (BARDA) for the development, production, and delivery of the University of Oxford's COVID-19 vaccine. However, many studies referred to different novel delivery systems, and positive outcomes from these studies significantly raised the market growth in the later phase of the pandemic. For instance, according to a research study published in the Biomedicine and Pharmacotherapy Journal in November 2021, nanoparticles were very useful in the drug delivery process for treating COVID-19. The study demonstrated that nanoparticles as delivery vehicles could improve drug delivery's effectiveness. Hence, the availability of such research fuelled the market growth in the later phase of the pandemic. This was expected to have a long-term impact of COVID-19 on the novel drug delivery systems (NDSS) market. The market is predicted to continue its growth trend over the forecast period.
The growth of the global novel drug delivery systems market is primarily driven by the rising need for a controlled drug delivery system owing to the increasing burden of chronic diseases such as diabetes, cardiovascular, renal disease, asthma, cancer, and others. With the increasing awareness about these diseases, the demand for effective and advanced therapeutics is increasing, which is expected to drive the companies to develop novel drug delivery systems and fuel the market's growth.
According to a research study published in the Journal of the Formosan Medical Association in October 2021, when a group of people aged 40 years to 74 years was studied, the overall prevalence rate of carotid plaque and diabetes mellitus (DM) was found to be 34.4% and 10.7%, respectively, while the age-specific prevalence rates of DM and carotid plaque were nearly linearly correlated in both genders among the studied population. This data shows a significant burden of several chronic diseases worldwide. Similarly, the Global Cancer Observatory Data updated in March 2021 showed that the global burden of cancer is expected to increase to 28.9 million by 2040 from 19.3 million in the most recent year data available. Hence, the high and increasing burden of chronic diseases is expected to lead the way for developing novel drug delivery systems with the new investments and advancements in the area and boost the studied market growth over the forecast period.
Moreover, the technological advancements in the drug delivery systems and new investment by the private as well as government entities, coupled with the new product launches, collaboration, and mergers and acquisitions by the key companies in the market, are further expected to boost growth in the novel drug delivery systems market. For instance, in June 2022, Gufic Biosciences Ltd. launched a novel Dual Chamber Bags (DCB) drug delivery system. These Dual Chamber Bags are 2-chamber IV bags made up of polypropylene (DEHP free) with a peelable aluminum foil, allowing the storage of unstable drugs that need reconstitution just before the administration to the patient. Therefore, owing to the abovementioned factors, the novel drug delivery systems market is expected to grow during the forecast period. However, stringent regulatory guidelines, product recalls, and stability issues are expected to restrain the growth of the studied market over the forecast period.
New Drug Delivery Systems (NDDS) Market Trends
Oral Drug Delivery Systems Segment is Expected to Occupy a Significant Share Over the Forecast Period
Oral medication administration methods are common due to their distinct features, such as continuous and controllable distribution, the convenience of administration, feasibility for solid formulations, patient compliance, cost-effectiveness, etc. The oral pathway received the most attention among the several drug delivery methods. With successful local and systemic effects, they are the most reliable routes for medication delivery and the ones that both doctors and patients prefer to use. Hence, the segment is growing and is expected to fuel the segment's growth.
Factors such as increasing research studies, clinical trials, and product launches by key market players will likely increase the segment's growth. For instance, as per the article by AstraZeneca in April 2023, most patients choose to use an oral formulation rather than an injection. Due to improvements in medication design and delivery methods, oral biologics are now becoming a reality. As per the above source, AstraZeneca has ongoing collaborations with the University of Uppsala through the SweDeliver Forum to understand better how Transient permeation enhancers (TPEs) can safely promote oral absorption of macromolecules as well as how to select the best TPEs for a particular macromolecule rationally. In addition, the company recently reported the potential of several approaches to enable the oral delivery of both peptides and antisense oligonucleotides. Thus, such activity and research in the segment are anticipated to drive the market's growth over the forecast period.
Moreover, product launches are another factor in market growth. For instance, in May 2022, Sun Pharma reported plans to launch an oral medication to reduce low-density lipoprotein (LDL) cholesterol. One of the company's wholly-owned subsidiaries planned to launch a first-in-class oral drug, Bempedoic Acid, in India for lowering LDL cholesterol. Thus, the oral drug delivery systems segment is expected to grow significantly over the forecast period due to the abovementioned factors.
North America is Expected to Account for Largest Market Share in the Novel Drug Delivery Systems Market
North America is expected to dominate the novel drug delivery systems market. North America is leading the market due to a rise in research activities about new therapies, an increased budget for novel drug discovery, and growing awareness about novel drug delivery systems.
Chronic diseases and conditions are on the rise in this region. For instance, according to the estimates of the Global Cancer Observatory report published in March 2021, there will be 2.3 million new cancer cases by 2045, and the most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer. Hence, the rising burden of cancer and other chronic diseases due to environmental and lifestyle changes is anticipated to create demand for innovative drug delivery options for the safe delivery of biologics and drive the market's growth over the forecast period.
In addition, several companies are focusing on the innovations of novel drug delivery systems, market expansion, and new product launches, which are expected to fuel market growth in the country. For instance, in May 2022, Jabil Healthcare launched the Qfinity autoinjector platform, a simple, reusable, and modular solution for subcutaneous (SC) drug self-administration at a lower cost than market alternatives that support the emerging prioritization of sustainable drug delivery within the pharmaceutical industry. Additionally, in October 2022, NuGen Medical Devices Inc., a market player in needle-free drug delivery, officially launched its InsuJet devices in Canada at the 2022 Diabetes Canada/Canadian Society of Endocrinology and Metabolism (CSEM) Professional Conference. Hence, such product launches are expected to increase regional market growth. Thus, the rising patient pool of chronic disorders and the development and launch of technologically advanced drug delivery systems are expected to drive North America's novel drug delivery systems market during the forecast period.
New Drug Delivery Systems (NDDS) Industry Overview
The NDDS market studied is a consolidated market due to major market players' presence. The market players are focusing on the development of innovative treatment options in order to grab maximum market share. Some of the market players are Abbott Laboratories, AstraZeneca PLC, Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., etc.
New Drug Delivery Systems (NDDS) Market Leaders
-
Abbott Laboratories
-
Bayer AG
-
F. Hoffmann-La Roche AG
-
GlaxoSmithKline Plc
-
Merck & Co., Inc
*Disclaimer: Major Players sorted in no particular order
New Drug Delivery Systems (NDDS) Market News
- June 2022: Esteve Pharmaceuticals GmbH launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor.
- June 2022: EVERSANA and Accord BioPharma partnered to support the recent launch of CAMCEVI (leuprolide) 42mg injection emulsion for treating advanced prostate cancer in adults.
New Drug Delivery Systems (NDDS) Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Need of Controlled Release of Drugs
- 4.2.2 Technological and Pharmacological Advancements Promoting the Development of NDDS
- 4.2.3 Rising Burden of Cancer Coupled with Increasing Researches in Novel Drug Delivery System for Cancer
-
4.3 Market Restraints
- 4.3.1 Stringent Regulatory Guidelines and Product Recalls
- 4.3.2 Stability Issues
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers/Consumers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Route of Administration
- 5.1.1 Oral Drug Delivery Systems
- 5.1.2 Injectable Drug Delivery Systems
- 5.1.3 Pulmonary Drug Delivery Systems
- 5.1.4 Transdermal Drug Delivery Systems
- 5.1.5 Other Routes of Administration
-
5.2 By Mode of NDDS
- 5.2.1 Targeted Drug Delivery Systems
- 5.2.2 Controlled Drug Delivery Systems
- 5.2.3 Modulated Drug Delivery Systems
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories
- 6.1.2 Amgen Inc
- 6.1.3 AstraZeneca PLC
- 6.1.4 Bayer AG
- 6.1.5 Boston Scientific Corporation
- 6.1.6 Bristol-Myers Squibb
- 6.1.7 Celgene Corporation
- 6.1.8 F. Hoffmann-La Roche AG
- 6.1.9 GlaxoSmithKline PLC
- 6.1.10 Johnson & Johnson
- 6.1.11 Merck & Co., Inc.,
- 6.1.12 Novartis AG
- 6.1.13 Pfizer Inc.
- 6.1.14 Spectrum Pharmaceuticals, Inc
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityNew Drug Delivery Systems (NDDS) Industry Segmentation
As per the scope of this report, the novel drug delivery system (NDDS) is intended to increase the efficacy of drugs. NDDSs are adopted to increase the bioavailability of the drug, reduce adverse effects and side effects, and increase drug stability. The Novel Drug Delivery Systems (NDDS) Market is segmented by Route of Administration (Oral Drug Delivery Systems, Injectable Drug Delivery Systems, Pulmonary Drug Delivery Systems, Transdermal Drug Delivery Systems, and Other Routes of Administration), Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug Delivery Systems), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Route of Administration | Oral Drug Delivery Systems | |
| Injectable Drug Delivery Systems | ||
| Pulmonary Drug Delivery Systems | ||
| Transdermal Drug Delivery Systems | ||
| Other Routes of Administration | ||
| By Mode of NDDS | Targeted Drug Delivery Systems | |
| Controlled Drug Delivery Systems | ||
| Modulated Drug Delivery Systems | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
New Drug Delivery Systems (NDDS) Market Research FAQs
What is the current Global Novel Drug Delivery Systems (NDDS) Market size?
The Global Novel Drug Delivery Systems (NDDS) Market is projected to register a CAGR of 5.46% during the forecast period (2024-2029)
Who are the key players in Global Novel Drug Delivery Systems (NDDS) Market?
Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc and Merck & Co., Inc are the major companies operating in the Global Novel Drug Delivery Systems (NDDS) Market.
Which is the fastest growing region in Global Novel Drug Delivery Systems (NDDS) Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Novel Drug Delivery Systems (NDDS) Market?
In 2024, the North America accounts for the largest market share in Global Novel Drug Delivery Systems (NDDS) Market.
What years does this Global Novel Drug Delivery Systems (NDDS) Market cover?
The report covers the Global Novel Drug Delivery Systems (NDDS) Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Novel Drug Delivery Systems (NDDS) Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
NDDS Industry Report
Statistics for the 2024 NDDS market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. NDDS analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
